KSB Q4 FY26 results: Revenue up 1%, profit down 24%

What KSB reported and why it matters

KSB Limited has announced its unaudited financial results for the quarter ended March 31, 2026 (Q4FY26), reporting modest year-on-year revenue growth but weaker profitability. The results showed that operating momentum softened on a sequential basis, even as sales held up compared with the same quarter last year. The company also disclosed consolidated and standalone figures, allowing investors to track the gap between the two sets of numbers. Alongside the earnings update, the broader set of filings in the provided text also includes compliance-related updates such as trading-window closures ahead of results disclosures.

Q4FY26 standalone performance: revenue growth, profit decline

For Q4FY26, KSB reported revenue from operations of ₹601.3 crore (₹6,013 million), up from ₹595.4 crore (₹5,954 million) in Q4FY25. Total income for the quarter came in at ₹615.6 crore (₹6,156 million), compared with ₹607.9 crore (₹6,079 million) a year earlier. Profit before tax (PBT) declined to ₹50.0 crore (₹500 million) from ₹65.5 crore (₹655 million) in Q4FY25. Net profit for the quarter fell to ₹37.3 crore (₹373 million) from ₹49.0 crore (₹490 million) in the year-ago quarter. The reported percentage change for net profit was a decline of 23.9% year-on-year.

Consolidated numbers: profit at ₹39.8 crore

On a consolidated basis, KSB reported Q4FY26 net profit of ₹39.8 crore (₹398 million), compared with ₹51.6 crore (₹516 million) in Q4FY25. Consolidated total income was reported at ₹615.7 crore (₹6,157 million) versus ₹607.9 crore (₹6,079 million) in the corresponding quarter last year. Consolidated profit before tax was ₹53.3 crore (₹533 million), down from ₹69.0 crore (₹690 million). The consolidated figures point to a similar direction as standalone results, with profitability declining despite a slight lift in income.

Sequential trend: sharp QoQ decline in key lines

KSB also disclosed quarter-on-quarter movements that highlight the sequential slowdown. Revenue from operations of ₹601.3 crore in Q4FY26 was reported as a 23.3% decline from ₹784.0 crore (₹7,840 million) in Q3FY26. Total income of ₹615.7 crore (₹6,157 million) was indicated as a 23.1% decline from ₹800.4 crore (₹8,004 million) in Q3FY26. Profit before tax (consolidated) of ₹53.3 crore in Q4FY26 was reported as down 50.7% sequentially from ₹108.2 crore (₹1,082 million) in Q3FY26. Profit for the period was cited at ₹39.3 crore (₹393 million) for Q4FY26, down 51.5% from ₹81.0 crore (₹810 million) in Q3FY26.

EPS and FY26 topline snapshot

The company reported earnings per equity share (basic and diluted) of ₹2.28 in Q4FY26, compared with ₹2.97 in Q4FY25 and ₹4.65 in Q3FY26. For FY26 on a consolidated basis, KSB reported revenue from operations of ₹2,695.7 crore (₹26,957 million) and total income of ₹2,754.9 crore (₹27,549 million). These full-year topline figures provide context for quarterly volatility, even though the detailed FY profit numbers were not included in the supplied text.

Audit and filing updates noted in the disclosures

KSB’s update described the Q4 2026 results as mixed, with year-on-year growth but quarter-on-quarter decline, and noted an unmodified limited review. Separately, the supplied text also references “KSB - Rectification in covering letter of results filed for quarter ended 31 March 2026,” signalling a procedural correction around results submission. The Board also appointed B S R & Co., as mentioned in the provided text. These items are typically tracked by investors because they relate to reporting processes and governance disclosures.

Key dates, dividend datapoint, and price mentioned

The supplied information lists the last earnings date as April 30, 2026 (Q4 FY25-26). It also flags an upcoming result date of August 4, 2026, and notes that the board meets on August 4, 2026 to approve Q1 and half-year unaudited results, alongside a trading-window closure. A dividend entry shows an XD-date of May 8, 2026 with a dividend amount of ₹4.4 per share, with the price on that day shown as ₹717.1. The text also states a current price for KSB Ltd of ₹946.20.

Separate BSE compliance update: Krebs Biochemicals trading window closure

In a separate filing referenced in the supplied text, Krebs Biochemicals & Industries Ltd said it closed its trading window for designated insiders from the close of business hours on June 30, 2026. The company stated the action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window is to remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The filing was submitted to BSE Limited and the National Stock Exchange of India Ltd on June 22, 2026. The same set of details is repeated in the text, reinforcing the compliance timeline.

Krebs financial context disclosed alongside the window closure

The supplied text also includes audited standalone results for Krebs for the fourth quarter and fiscal year ended March 31, 2026. Krebs reported a net loss of ₹2.34 crore (₹233.96 lacs) for the quarter and ₹16.93 crore (₹1,693.31 lacs) for the full year. The annual loss was narrower than the previous year’s loss of ₹26.94 crore (₹2,693.93 lacs), based on the figures provided. These numbers set context for the company’s ongoing financial position, while the trading-window closure sets the compliance perimeter ahead of the next quarterly disclosure.

Summary table of the main reported numbers and dates

What investors will track next

For KSB, the next milestone highlighted is the board meeting scheduled for August 4, 2026 to approve Q1 and half-year unaudited results, along with the related trading-window closure referenced in the text. For Krebs Biochemicals, the focus is on the timing of the Q1 results for the quarter ended June 30, 2026, after which the trading window is set to reopen 48 hours later. Both sets of disclosures underline the importance of results timelines and compliance steps around price-sensitive information.

Conclusion

KSB’s Q4FY26 results showed small year-on-year revenue growth but a marked decline in profitability, alongside a steep quarter-on-quarter fall in both revenue and profit metrics from Q3FY26 levels. Separately, Krebs Biochemicals’ filing highlighted a trading-window closure tied to the upcoming June-quarter results and also provided audited loss figures for FY26. The next confirmed calendar event in the provided information is the August 4, 2026 results approval meeting for KSB, while Krebs’ trading window is set to reopen only after its June-quarter results are declared and the 48-hour cooling-off period passes.